Open Payments

JEAN FOUCAULD

Type
Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease
Where
OKEECHOBEE, FL
NPI
1164414900
Received
$37,128 in 412 records, 2019 to 2025 ($15,829 general, $21,298 research)
As principal investigator
$3,455,459 of research payments to others in 407 records
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025General payment58$2,201
2024General payment67$4,307
2024Research payment2$21,298
2023General payment69$4,118
2022General payment50$1,781
2021General payment79$1,464
2020General payment35$935
2019General payment52$1,020

By company

CompanyRecordsAmountYears
Eli Lilly and Company21$23,8872024
Novartis Pharmaceuticals Corporation52$3,4082019–2025
Janssen Research & Development, LLC21$2,1932023
Amgen Inc.47$8342019–2025
Abbott Laboratories16$8242019–2025
Bayer Healthcare Pharmaceuticals Inc.39$7002021–2025
AstraZeneca Pharmaceuticals LP15$6102019–2024
Astellas Pharma US Inc9$5182019–2022
E.R. Squibb & Sons, L.L.C.19$3992019–2025
Janssen Pharmaceuticals, Inc38$3982019–2024
CVRx, Inc.18$3852023–2025
Merck Sharp & Dohme LLC16$3522021–2025
Medtronic, Inc.2$2952024
Amarin Pharma, Inc.18$2892019–2021
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)15$2652019–2025
Kestra Medical Technology Services, Inc.5$2252024–2025
HEARTFLOW, INC.4$2002022–2024
SANOFI-AVENTIS U.S. LLC10$1882019–2021
PFIZER INC.10$1642019–2025
Cardiac Dimensions, Inc.1$1312025
Biosense Webster, Inc.1$1262024
Boston Scientific Corporation4$1082021–2025
Bard Peripheral Vascular, Inc.3$1082022–2024
Esperion Therapeutics, Inc.6$852020–2025
Boehringer Ingelheim Pharmaceuticals, Inc.5$842019–2025
Lexicon Pharmaceuticals, Inc.3$682024
Kiniksa Pharmaceuticals, Ltd.2$572022
Novo Nordisk Inc2$362021–2025
Arbor Pharmaceuticals, Inc.2$362019–2021
Cleerly, Inc.2$352025
Kowa Pharmaceuticals America, Inc.1$252021
AGEPHA Pharma FZ LLC1$192024
Inspire Medical Systems, Inc.1$182024
Becton, Dickinson and Company1$152024
Bardy Diagnostics, Inc.1$152022
Chiesi USA, Inc.1$102019

By nature of payment

NatureRecordsAmount
Research payment2$21,298
Food and Beverage371$9,996
Travel and Lodging32$5,374
Education7$458

Records

DateCompanyAmountNatureFormProductStudyYear
2025-12-17E.R. Squibb & Sons, L.L.C.$4Food and BeverageCash or cash equivalentCAMZYOS Drug, Cardiovascular2025
2025-12-11Kestra Medical Technology Services, Inc.$33Food and BeverageCash or cash equivalentAssure WCD Device, Cardiology/Vascular Diseases2025
2025-12-11E.R. Squibb & Sons, L.L.C.$5Food and BeverageCash or cash equivalentCAMZYOS Drug, Cardiovascular2025
2025-11-13Boehringer Ingelheim Pharmaceuticals, Inc.$13Food and BeverageIn-kind items and servicesJARDIANCE Drug, DIABETES2025
2025-11-12Bayer Healthcare Pharmaceuticals Inc.$34Food and BeverageIn-kind items and servicesKerendia Drug, Cardio-Renal2025
2025-10-31Abbott Laboratories$19Food and BeverageIn-kind items and servicesAMPLATZER AMULET Device, Structural Heart2025
2025-10-29Boehringer Ingelheim Pharmaceuticals, Inc.$15Food and BeverageIn-kind items and servicesJARDIANCE Drug, DIABETES2025
2025-10-16E.R. Squibb & Sons, L.L.C.$3Food and BeverageCash or cash equivalentCAMZYOS Drug, Cardiovascular2025
2025-10-15Merck Sharp & Dohme LLC$26Food and BeverageIn-kind items and servicesCAPVAXIVE Biological, VACCINE2025
2025-10-14Abbott Laboratories$142Food and BeverageIn-kind items and servicesENSITE Device, Structural Heart2025
2025-10-02PFIZER INC.$27Food and BeverageIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULAR2025
2025-09-26CVRx, Inc.$7Food and BeverageCash or cash equivalentBarostim Neo System Device, Heart Failure and Hypertension2025
2025-09-17CVRx, Inc.$15Food and BeverageCash or cash equivalentBarostim Neo System Device, Heart Failure and Hypertension2025
2025-09-15Abbott Laboratories$24Food and BeverageIn-kind items and servicesCARDIOMEMS Device, Structural Heart2025
2025-09-11Novartis Pharmaceuticals Corporation$16Food and BeverageIn-kind items and servicesLEQVIO Drug, Cardiology/Vascular Diseases2025
2025-09-11Novartis Pharmaceuticals Corporation$3Food and BeverageIn-kind items and servicesLEQVIO Drug, Cardiology/Vascular Diseases2025
2025-09-04Merck Sharp & Dohme LLC$19Food and BeverageIn-kind items and servicesVERQUVO Drug, CARDIOVASCULAR2025
2025-08-28ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)$20Food and BeverageCash or cash equivalentLifeVest Device, Electromedical and Electrotherapeutic Apparatus2025
2025-08-28E.R. Squibb & Sons, L.L.C.$5Food and BeverageCash or cash equivalentCAMZYOS Drug, Cardiovascular2025
2025-08-21E.R. Squibb & Sons, L.L.C.$10Food and BeverageCash or cash equivalentCAMZYOS Drug, Cardiovascular2025
2025-08-13Novartis Pharmaceuticals Corporation$5Food and BeverageIn-kind items and servicesLEQVIO Drug, Cardiology/Vascular Diseases2025
2025-08-07Abbott Laboratories$24Food and BeverageIn-kind items and servicesAVEIR Device, Structural Heart2025
2025-07-23Bayer Healthcare Pharmaceuticals Inc.$33Food and BeverageIn-kind items and servicesKerendia Drug, Cardio-Renal2025
2025-07-23E.R. Squibb & Sons, L.L.C.$3Food and BeverageCash or cash equivalentCAMZYOS Drug, Cardiovascular2025
2025-07-17Boston Scientific Corporation$28Food and BeverageIn-kind items and servicesAMS 700 Device, AMS 700_URO2025
2025-07-16Cleerly, Inc.$15Food and BeverageCash or cash equivalentCleerly Ischemia Device, Cardiology/Vascular Diseases2025
2025-07-10Merck Sharp & Dohme LLC$21Food and BeverageIn-kind items and servicesVERQUVO Drug, CARDIOVASCULAR2025
2025-07-03CVRx, Inc.$15Food and BeverageCash or cash equivalentBarostim Neo System Device, Heart Failure and Hypertension2025
2025-06-26Cleerly, Inc.$20Food and BeverageCash or cash equivalentCleerly Ischemia Device, Cardiology/Vascular Diseases2025
2025-06-21Novartis Pharmaceuticals Corporation$244Travel and LodgingIn-kind items and services2025
2025-06-21Novartis Pharmaceuticals Corporation$215Food and BeverageIn-kind items and services2025
2025-06-21Novartis Pharmaceuticals Corporation$214Travel and LodgingIn-kind items and services2025
2025-06-21Novartis Pharmaceuticals Corporation$34Food and BeverageCash or cash equivalent2025
2025-06-20Novartis Pharmaceuticals Corporation$133Food and BeverageIn-kind items and services2025
2025-06-18CVRx, Inc.$16Food and BeverageCash or cash equivalentBarostim Neo System Device, Heart Failure and Hypertension2025
2025-06-18Novartis Pharmaceuticals Corporation$9Food and BeverageIn-kind items and servicesLEQVIO Drug, Cardiology/Vascular Diseases2025
2025-06-18Novartis Pharmaceuticals Corporation$3Food and BeverageIn-kind items and servicesLEQVIO Drug, Cardiology/Vascular Diseases2025
2025-06-18E.R. Squibb & Sons, L.L.C.$2Food and BeverageCash or cash equivalentCAMZYOS Drug, Cardiovascular2025
2025-06-12Bayer Healthcare Pharmaceuticals Inc.$24Food and BeverageIn-kind items and servicesKerendia Drug, Cardio-Renal2025
2025-06-11E.R. Squibb & Sons, L.L.C.$16Food and BeverageCash or cash equivalentELIQUIS Drug, Cardiovascular2025
2025-05-22ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)$20Food and BeverageCash or cash equivalentLifeVest Device, Electromedical and Electrotherapeutic Apparatus2025
2025-05-20Kestra Medical Technology Services, Inc.$43Food and BeverageCash or cash equivalentAssure WCD Device, Cardiology/Vascular Diseases2025
2025-05-13ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)$20Food and BeverageCash or cash equivalentLifeVest Device, Electromedical and Electrotherapeutic Apparatus2025
2025-05-02CVRx, Inc.$17Food and BeverageCash or cash equivalentBarostim Neo System Device, Heart Failure and Hypertension2025
2025-04-30E.R. Squibb & Sons, L.L.C.$15Food and BeverageCash or cash equivalentCAMZYOS Drug, Cardiovascular2025
2025-04-29Kestra Medical Technology Services, Inc.$46Food and BeverageCash or cash equivalentAssure WCD Device, Cardiology/Vascular Diseases2025
2025-04-16Esperion Therapeutics, Inc.$16Food and BeverageIn-kind items and servicesNEXLETOL Drug, ANTILIPEMIC AGENTS2025
2025-04-11CVRx, Inc.$5Food and BeverageCash or cash equivalentBarostim Neo System Device, Heart Failure and Hypertension2025
2025-04-03E.R. Squibb & Sons, L.L.C.$126Food and BeverageCash or cash equivalentCAMZYOS Drug, Cardiovascular2025
2025-04-02Bayer Healthcare Pharmaceuticals Inc.$24Food and BeverageIn-kind items and servicesKerendia Drug, Cardio-Renal2025
2025-03-12Cardiac Dimensions, Inc.$131Food and BeverageIn-kind items and services2025
2025-03-05Bayer Healthcare Pharmaceuticals Inc.$23Food and BeverageIn-kind items and servicesKerendia Drug, Cardio-Renal2025
2025-03-05E.R. Squibb & Sons, L.L.C.$18Food and BeverageCash or cash equivalentCAMZYOS Drug, Cardiovascular2025
2025-02-20CVRx, Inc.$20Food and BeverageCash or cash equivalentBarostim Neo System Device, Heart Failure and Hypertension2025
2025-02-19Amgen Inc.$19Food and BeverageIn-kind items and servicesREPATHA Biological, Cardiovascular2025
2025-02-13Novo Nordisk Inc$22Food and BeverageIn-kind items and services2025
2025-02-05CVRx, Inc.$16Food and BeverageCash or cash equivalentBarostim Neo System Device, Heart Failure and Hypertension2025
2025-02-03Kestra Medical Technology Services, Inc.$79Food and BeverageCash or cash equivalentAssure WCD Device, Cardiology/Vascular Diseases2025
2024-12-27CVRx, Inc.$7Food and BeverageCash or cash equivalentBarostim Neo System Device, Heart Failure and Hypertension2024
2024-12-03Bayer Healthcare Pharmaceuticals Inc.$20Food and BeverageIn-kind items and servicesKerendia Drug, Cardio-renal2024
2024-11-26CVRx, Inc.$13Food and BeverageCash or cash equivalentBarostim Neo System Device, Heart Failure and Hypertension2024
2024-11-14CVRx, Inc.$8Food and BeverageCash or cash equivalentBarostim Neo System Device, Heart Failure and Hypertension2024
2024-11-12HEARTFLOW, INC.$28Food and BeverageCash or cash equivalentFFRct Device, Coronary2024
2024-11-12Amgen Inc.$5Food and BeverageIn-kind items and servicesRepatha Biological, Cardiology2024
2024-10-23HEARTFLOW, INC.$29Food and BeverageCash or cash equivalentFFRct Device, Coronary2024
2024-10-21Medtronic, Inc.$133Food and BeverageIn-kind items and servicesAZURE XT DR MRI SURESCAN Device, Pacemakers2024
2024-10-16CVRx, Inc.$13Food and BeverageCash or cash equivalentBarostim Neo System Device, Heart Failure and Hypertension2024
2024-10-15Amgen Inc.$6Food and BeverageIn-kind items and servicesRepatha Biological, Cardiology2024
2024-09-26Eli Lilly and Company$184Food and BeverageCash or cash equivalent2024
2024-09-24Eli Lilly and Company$19,410Research paymentCash or cash equivalentA PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION 2024
2024-09-19Bayer Healthcare Pharmaceuticals Inc.$20Food and BeverageIn-kind items and servicesKerendia Drug, Cardio-renal2024
2024-09-18E.R. Squibb & Sons, L.L.C.$14Food and BeverageCash or cash equivalentELIQUIS Drug, Cardiovascular2024
2024-08-27Bayer Healthcare Pharmaceuticals Inc.$21Food and BeverageIn-kind items and servicesKerendia Drug, Cardio-renal2024
2024-08-08CVRx, Inc.$15Food and BeverageCash or cash equivalentBarostim Neo System Device, Heart Failure and Hypertension2024
2024-08-07Inspire Medical Systems, Inc.$18Food and BeverageIn-kind items and servicesINSPIRE Device, NEUROLOGY2024
2024-08-06Lexicon Pharmaceuticals, Inc.$19Food and BeverageIn-kind items and services2024
2024-07-30Amgen Inc.$18Food and BeverageIn-kind items and servicesRepatha Biological, Cardiology2024
2024-07-12Abbott Laboratories$102Food and BeverageIn-kind items and servicesAMPLATZER AMULET Device, Structural Heart2024
2024-07-09Abbott Laboratories$14Food and BeverageIn-kind items and servicesAVEIR Device, Cardiac Rhythm Management2024
2024-07-09CVRx, Inc.$14Food and BeverageCash or cash equivalentBarostim Neo System Device, Heart Failure and Hypertension2024
2024-07-02Janssen Pharmaceuticals, Inc$15Food and BeverageIn-kind items and servicesXARELTO Drug, Cardiovascular & Metabolism2024
2024-06-27Bayer Healthcare Pharmaceuticals Inc.$20Food and BeverageIn-kind items and servicesKerendia Drug, Cardio-renal2024
2024-06-20Eli Lilly and Company$1,888Research paymentIn-kind items and servicesA PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION 2024
2024-06-20Becton, Dickinson and Company$15Food and BeverageIn-kind items and servicesVenclose Maven Catheter Device, Vascular/Oncology2024
2024-06-17Eli Lilly and Company$339Travel and LodgingIn-kind items and services2024
2024-06-17Eli Lilly and Company$339Travel and LodgingIn-kind items and services2024
2024-06-17Eli Lilly and Company$320Travel and LodgingIn-kind items and services2024
2024-06-17Eli Lilly and Company$118Food and BeverageIn-kind items and services2024
2024-06-17Eli Lilly and Company$51Food and BeverageIn-kind items and services2024
2024-06-17Eli Lilly and Company$51Food and BeverageIn-kind items and services2024
2024-06-17Eli Lilly and Company$42Travel and LodgingIn-kind items and services2024
2024-06-17Eli Lilly and Company$42Travel and LodgingIn-kind items and services2024
2024-06-17Eli Lilly and Company$32Food and BeverageIn-kind items and services2024
2024-06-17Eli Lilly and Company$32Food and BeverageIn-kind items and services2024
2024-06-17Eli Lilly and Company$32Travel and LodgingIn-kind items and services2024
2024-06-17Eli Lilly and Company$15Travel and LodgingIn-kind items and services2024
2024-06-17Eli Lilly and Company$14Food and BeverageIn-kind items and services2024
2024-06-17Eli Lilly and Company$14Food and BeverageIn-kind items and services2024
2024-06-16Eli Lilly and Company$359Travel and LodgingIn-kind items and services2024
2024-06-16Eli Lilly and Company$322Travel and LodgingIn-kind items and services2024
2024-06-16Eli Lilly and Company$151Travel and LodgingIn-kind items and services2024
2024-06-16Eli Lilly and Company$123Travel and LodgingIn-kind items and services2024
2024-06-11Amgen Inc.$116Food and BeverageIn-kind items and servicesRepatha Biological, Cardiology2024
2024-06-04Novartis Pharmaceuticals Corporation$18Food and BeverageIn-kind items and servicesLEQVIO Drug, Cardiology/Vascular Diseases2024
2024-06-04Boehringer Ingelheim Pharmaceuticals, Inc.$17Food and BeverageIn-kind items and servicesJARDIANCE Drug, DIABETES2024
2024-05-30Bayer Healthcare Pharmaceuticals Inc.$18Food and BeverageIn-kind items and servicesKerendia Drug, Cardio-renal2024
2024-05-29Amgen Inc.$8Food and BeverageIn-kind items and servicesRepatha Biological, Cardiology2024
2024-05-23Biosense Webster, Inc.$126Food and BeverageIn-kind items and servicesCARTO 3 Device, Cardiology2024
2024-05-21Lexicon Pharmaceuticals, Inc.$23Food and BeverageIn-kind items and services2024
2024-05-14CVRx, Inc.$17Food and BeverageCash or cash equivalentBarostim Neo System Device, Heart Failure and Hypertension2024
2024-05-01Lexicon Pharmaceuticals, Inc.$25Food and BeverageIn-kind items and services2024
2024-04-17CVRx, Inc.$145Food and BeverageCash or cash equivalentBarostim Neo System Device, Heart Failure and Hypertension2024
2024-04-09Bayer Healthcare Pharmaceuticals Inc.$20Food and BeverageIn-kind items and servicesKerendia Drug, Cardio-renal2024
2024-04-03AstraZeneca Pharmaceuticals LP$62Food and BeverageIn-kind items and services2024
2024-04-03Amgen Inc.$25Food and BeverageIn-kind items and servicesRepatha Biological, Cardiology2024
2024-04-02AGEPHA Pharma FZ LLC$19Food and BeverageIn-kind items and servicesLODOCO Drug, Cardiovascular Diseases2024
2024-03-14Abbott Laboratories$18Food and BeverageIn-kind items and servicesAMPLATZER AMULET Device, Structural Heart2024
2024-03-04Bayer Healthcare Pharmaceuticals Inc.$19Food and BeverageIn-kind items and servicesKerendia Drug, Cardio-renal2024
2024-03-01Abbott Laboratories$139Food and BeverageIn-kind items and servicesAMPLATZER TALISMAN Device, Structural Heart2024
2024-02-20Bayer Healthcare Pharmaceuticals Inc.$15Food and BeverageIn-kind items and servicesKerendia Drug, Cardio-renal2024
2024-02-13Bard Peripheral Vascular, Inc.$22Food and BeverageIn-kind items and servicesVenclose Maven Catheter Device, Vascular/Oncology2024
2024-02-07Medtronic, Inc.$161Food and BeverageIn-kind items and servicesLINQ II Device, Cardiac Diagnostics and Monitoring2024
2024-01-24Kestra Medical Technology Services, Inc.$23Food and BeverageCash or cash equivalentAssure WCD Device, Cardiology2024
2024-01-24Amgen Inc.$7Food and BeverageIn-kind items and servicesRepatha Biological, Cardiology2024
2024-01-16ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)$49Food and BeverageCash or cash equivalentLifeVest Device, Electromedical and Electrotherapeutic Apparatus2024
2024-01-16ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)$18Food and BeverageCash or cash equivalentLifeVest Device, Electromedical and Electrotherapeutic Apparatus2024
2024-01-11Bayer Healthcare Pharmaceuticals Inc.$16Food and BeverageIn-kind items and servicesKerendia Drug, Cardio-renal2024
2023-12-20E.R. Squibb & Sons, L.L.C.$10Food and BeverageCash or cash equivalentCAMZYOS Drug, Cardiovascular2023
2023-12-13Merck Sharp & Dohme LLC$16Food and BeverageIn-kind items and servicesVERQUVO Drug, CARDIOVASCULAR2023
2023-11-21CVRx, Inc.$15Food and BeverageCash or cash equivalentBarostim Neo System Device, Heart Failure and Hypertension2023
2023-11-01Abbott Laboratories$14Food and BeverageIn-kind items and servicesAVEIR Device, Cardiac Rhythm Management2023
2023-10-24ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)$21Food and BeverageCash or cash equivalentLifeVest Device, Electromedical and Electrotherapeutic Apparatus2023
2023-10-19Merck Sharp & Dohme LLC$16Food and BeverageIn-kind items and servicesVERQUVO Drug, CARDIOVASCULAR2023
2023-10-10Bayer Healthcare Pharmaceuticals Inc.$14Food and BeverageIn-kind items and servicesKerendia Drug, Cardio-renal2023
2023-10-06PFIZER INC.$13Food and BeverageIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULAR2023
2023-10-03Novartis Pharmaceuticals Corporation$19Food and BeverageIn-kind items and servicesENTRESTO Drug, Cardiology/Vascular Diseases2023
2023-09-28E.R. Squibb & Sons, L.L.C.$114Food and BeverageCash or cash equivalentCAMZYOS Drug, Cardiovascular2023
2023-09-20Boehringer Ingelheim Pharmaceuticals, Inc.$17Food and BeverageIn-kind items and servicesJARDIANCE Drug, DIABETES2023
2023-09-19E.R. Squibb & Sons, L.L.C.$15Food and BeverageCash or cash equivalentELIQUIS Drug, Cardiovascular2023
2023-08-29CVRx, Inc.$17Food and BeverageCash or cash equivalentBarostim Neo System Device, Heart Failure and Hypertension2023
2023-08-18PFIZER INC.$15Food and BeverageIn-kind items and servicesVYNDAMAX Drug, CARDIOVASCULAR2023
2023-08-15Bayer Healthcare Pharmaceuticals Inc.$16Food and BeverageIn-kind items and servicesKerendia Drug, Cardio-renal2023
2023-08-09Amgen Inc.$25Food and BeverageIn-kind items and servicesRepatha Biological, Cardiology2023
2023-08-08Merck Sharp & Dohme LLC$14Food and BeverageIn-kind items and servicesVERQUVO Drug, CARDIOVASCULAR2023
2023-08-01Novartis Pharmaceuticals Corporation$16Food and BeverageIn-kind items and servicesLEQVIO Drug, Cardiology/Vascular Diseases2023
2023-07-28ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)$7Food and BeverageCash or cash equivalentLifeVest Device, Electromedical and Electrotherapeutic Apparatus2023
2023-07-27PFIZER INC.$14Food and BeverageIn-kind items and servicesVYNDAQEL Drug, CARDIOVASCULAR2023
2023-07-27E.R. Squibb & Sons, L.L.C.$7Food and BeverageCash or cash equivalentELIQUIS Drug, Cardiovascular2023
2023-07-11Bayer Healthcare Pharmaceuticals Inc.$15Food and BeverageIn-kind items and servicesKerendia Drug, Cardio-renal2023
2023-07-05Novartis Pharmaceuticals Corporation$8Food and BeverageIn-kind items and servicesLEQVIO Drug, Cardiology/Vascular Diseases2023
2023-06-27Merck Sharp & Dohme LLC$15Food and BeverageIn-kind items and servicesVERQUVO Drug, CARDIOVASCULAR2023
2023-06-01Bayer Healthcare Pharmaceuticals Inc.$16Food and BeverageIn-kind items and servicesKerendia Drug, Cardio-renal2023
2023-06-01Merck Sharp & Dohme LLC$14Food and BeverageIn-kind items and servicesVERQUVO Drug, CARDIOVASCULAR2023
2023-05-18Janssen Research & Development, LLC$292Travel and LodgingIn-kind items and services2023
2023-05-18Janssen Research & Development, LLC$292Travel and LodgingIn-kind items and services2023
2023-05-18Janssen Research & Development, LLC$125Food and BeverageIn-kind items and services2023
2023-05-18Janssen Research & Development, LLC$60Food and BeverageIn-kind items and services2023
2023-05-18Janssen Research & Development, LLC$41Travel and LodgingIn-kind items and services2023
2023-05-18Janssen Research & Development, LLC$40Travel and LodgingIn-kind items and services2023
2023-05-18Janssen Research & Development, LLC$40Food and BeverageIn-kind items and services2023
2023-05-18Janssen Research & Development, LLC$25Food and BeverageIn-kind items and services2023
2023-05-18Janssen Research & Development, LLC$20Food and BeverageIn-kind items and services2023
2023-05-18Janssen Research & Development, LLC$20Food and BeverageIn-kind items and services2023
2023-05-17Janssen Research & Development, LLC$292Travel and LodgingIn-kind items and services2023
2023-05-17Janssen Research & Development, LLC$125Food and BeverageIn-kind items and services2023
2023-05-17Janssen Research & Development, LLC$60Food and BeverageIn-kind items and services2023
2023-05-17Janssen Research & Development, LLC$41Travel and LodgingIn-kind items and services2023
2023-05-17Janssen Research & Development, LLC$41Travel and LodgingIn-kind items and services2023
2023-05-17Janssen Research & Development, LLC$40Food and BeverageIn-kind items and services2023
2023-05-17Janssen Research & Development, LLC$25Food and BeverageIn-kind items and services2023
2023-05-17Janssen Research & Development, LLC$20Food and BeverageIn-kind items and services2023
2023-05-17Janssen Research & Development, LLC$20Food and BeverageIn-kind items and services2023
2023-05-12E.R. Squibb & Sons, L.L.C.$1Food and BeverageCash or cash equivalentCAMZYOS Drug, Cardiovascular2023
2023-05-09AstraZeneca Pharmaceuticals LP$22Food and BeverageIn-kind items and servicesFARXIGA Drug, Cardiovascular and Metabolism2023
2023-05-04E.R. Squibb & Sons, L.L.C.$9Food and BeverageCash or cash equivalentELIQUIS Drug, Cardiovascular2023
2023-04-24Janssen Research & Development, LLC$286Travel and LodgingIn-kind items and services2023
2023-04-24Janssen Research & Development, LLC$286Travel and LodgingIn-kind items and services2023
2023-04-18Amgen Inc.$18Food and BeverageIn-kind items and servicesRepatha Biological, Cardiology2023
2023-04-18Amgen Inc.$17EducationIn-kind items and services2023
2023-04-04Bayer Healthcare Pharmaceuticals Inc.$16Food and BeverageIn-kind items and servicesKerendia Drug, Cardio-renal2023
2023-03-27Boston Scientific Corporation$30Food and BeverageIn-kind items and servicesWATCHMAN Access System Device, WATCHMAN_IC2023
2023-03-23Novartis Pharmaceuticals Corporation$21Food and BeverageIn-kind items and servicesENTRESTO Drug, Cardiology/Vascular Diseases2023
2023-03-21HEARTFLOW, INC.$128Food and BeverageCash or cash equivalentFFRct Device, Coronary2023
2023-03-11Novartis Pharmaceuticals Corporation$223Food and BeverageIn-kind items and servicesLEQVIO Drug, Cardiology/Vascular Diseases2023
2023-03-11Novartis Pharmaceuticals Corporation$221Travel and LodgingIn-kind items and servicesLEQVIO Drug, Cardiology/Vascular Diseases2023
2023-03-11Novartis Pharmaceuticals Corporation$39Travel and LodgingCash or cash equivalentLEQVIO Drug, Cardiology/Vascular Diseases2023
2023-03-11Novartis Pharmaceuticals Corporation$37Food and BeverageIn-kind items and servicesLEQVIO Drug, Cardiology/Vascular Diseases2023
2023-03-11Novartis Pharmaceuticals Corporation$32Travel and LodgingIn-kind items and servicesLEQVIO Drug, Cardiology/Vascular Diseases2023
2023-03-11Novartis Pharmaceuticals Corporation$14Travel and LodgingIn-kind items and servicesLEQVIO Drug, Cardiology/Vascular Diseases2023
2023-03-10Novartis Pharmaceuticals Corporation$390Travel and LodgingIn-kind items and servicesLEQVIO Drug, Cardiology/Vascular Diseases2023
2023-03-10Novartis Pharmaceuticals Corporation$124Food and BeverageIn-kind items and servicesLEQVIO Drug, Cardiology/Vascular Diseases2023
2023-03-02Merck Sharp & Dohme LLC$17Food and BeverageIn-kind items and servicesVERQUVO Drug, CARDIOVASCULAR2023
2023-02-28Amgen Inc.$20Food and BeverageIn-kind items and servicesRepatha Biological, Cardiology2023
2023-02-14Novartis Pharmaceuticals Corporation$7Food and BeverageIn-kind items and servicesENTRESTO Drug, Cardiology/Vascular Diseases2023
2023-02-10Bayer Healthcare Pharmaceuticals Inc.$15Food and BeverageIn-kind items and servicesKerendia Drug, Cardio-renal2023
2023-01-03Bayer Healthcare Pharmaceuticals Inc.$16Food and BeverageIn-kind items and servicesKerendia Drug, Cardio-renal2023
2022-11-17Bardy Diagnostics, Inc.$15Food and BeverageIn-kind items and servicesCarnation Ambulatory Monitor Device, Cardiac Arrhythmia Monitoring2022
2022-11-12Novartis Pharmaceuticals Corporation$224Travel and LodgingIn-kind items and services2022
2022-11-12Novartis Pharmaceuticals Corporation$171Food and BeverageIn-kind items and services2022
2022-11-12Novartis Pharmaceuticals Corporation$24Travel and LodgingIn-kind items and services2022

The latest 200 records of 412.

Research payments naming this person as principal investigator

DateCompanyPaid toAmountStudyYear
2025-12-17Novartis Pharmaceuticals CorporationCARDIOLOGY PARTNERS CLINICAL RESEARCH INSTITUTE$121A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With T2025
2025-12-12Janssen Research & Development, LLCCrdlgy Partners-Wellington Ofc$11,628A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and 2025
2025-12-12Boehringer Ingelheim International GmbHCardiology Partners Palm Beach Gardens Office$169EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety o2025
2025-12-12Boehringer Ingelheim International GmbHCardiology Partners Palm Beach Gardens Office$217EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety o2025
2025-12-12Boehringer Ingelheim International GmbHCardiology Partners Palm Beach Gardens Office$3,087EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety o2025
2025-12-12Boehringer Ingelheim International GmbHCardiology Partners Palm Beach Gardens Office$2,243EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety o2025
2025-12-12Boehringer Ingelheim International GmbHCardiology Partners Palm Beach Gardens Office$382EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety o2025
2025-12-12Boehringer Ingelheim International GmbHCardiology Partners Palm Beach Gardens Office$169EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety o2025
2025-12-12Boehringer Ingelheim International GmbHCardiology Partners Palm Beach Gardens Office$217EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety o2025
2025-12-12Boehringer Ingelheim International GmbHCardiology Partners Palm Beach Gardens Office$3,087EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety o2025
2025-12-12Boehringer Ingelheim International GmbHCardiology Partners Palm Beach Gardens Office$2,243EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety o2025
2025-12-12Boehringer Ingelheim International GmbHCardiology Partners Palm Beach Gardens Office$3,583EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety o2025
2025-12-12Boehringer Ingelheim International GmbHCardiology Partners Palm Beach Gardens Office$3,583EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety o2025
2025-12-12Janssen Research & Development, LLCCrdlgy Partners-Wellington Ofc$516A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)2025
2025-11-19Janssen Research & Development, LLCCrdlgy Partners-Wellington Ofc$12,335A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and 2025
2025-11-19Boehringer Ingelheim International GmbHCardiology Partners Palm Beach Gardens Office$859EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety o2025
2025-11-19Boehringer Ingelheim International GmbHCardiology Partners Palm Beach Gardens Office$69EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety o2025
2025-11-11Boehringer Ingelheim Pharma GmbH & Co.KGCardiology Partners Palm Beach Gardens Office$1,669EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety o2025
2025-11-11Boehringer Ingelheim Pharma GmbH & Co.KGCardiology Partners Palm Beach Gardens Office$1,669EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety o2025
2025-11-07Janssen Research & Development, LLCCrdlgy Partners-Wellington Ofc$16,515A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and 2025
2025-11-05Janssen Research & Development, LLCCrdlgy Partners-Wellington Ofc$6,594A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and 2025
2025-10-22Janssen Research & Development, LLCCrdlgy Partners-Wellington Ofc$2,928A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)2025
2025-09-19Janssen Research & Development, LLCCrdlgy Partners-Wellington Ofc$21,236A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and 2025
2025-09-19Janssen Research & Development, LLCCrdlgy Partners-Wellington Ofc$2,136A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)2025
2025-09-03Janssen Research & Development, LLCCrdlgy Partners-Wellington Ofc$3,064A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)2025
2025-08-25Janssen Research & Development, LLCCrdlgy Partners-Wellington Ofc$528A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)2025
2025-08-25Janssen Research & Development, LLCCrdlgy Partners-Wellington Ofc$14,004A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and 2025
2025-08-22Janssen Research & Development, LLCCrdlgy Partners-Wellington Ofc$2,963A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)2025
2025-08-12Boehringer Ingelheim Pharma GmbH & Co.KGCardiology Partners Palm Beach Gardens Office$6,676EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety o2025
2025-07-28Boehringer Ingelheim International GmbHCardiology Partners Palm Beach Gardens Office$34EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety o2025
2025-07-28Boehringer Ingelheim International GmbHCardiology Partners Palm Beach Gardens Office$359EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety o2025
2025-07-28Boehringer Ingelheim International GmbHCardiology Partners Palm Beach Gardens Office$36EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety o2025
2025-07-23Janssen Research & Development, LLCCrdlgy Partners-Wellington Ofc$1,728A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)2025
2025-07-23Janssen Research & Development, LLCCrdlgy Partners-Wellington Ofc$6,084A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and 2025
2025-07-22Amgen Inc.CARDIOLOGY PARTNERS CLINICAL RESEARCH INSTITUTE$1,274A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglut2025
2025-07-08Novartis Pharmaceuticals CorporationCARDIOLOGY PARTNERS, LLC$42,690A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and 2025
2025-06-25Janssen Research & Development, LLCCrdlgy Partners-Wellington Ofc$5,909A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and 2025
2025-06-23Janssen Research & Development, LLCCrdlgy Partners-Wellington Ofc$7,744A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and 2025
2025-06-20Janssen Research & Development, LLCCrdlgy Partners-Wellington Ofc$20,806A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and 2025
2025-06-20Janssen Research & Development, LLCCrdlgy Partners-Wellington Ofc$1,501A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)2025
2025-05-21Janssen Research & Development, LLCCrdlgy Partners-Wellington Ofc$10,005A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and 2025
2025-05-16Janssen Research & Development, LLCCrdlgy Partners-Wellington Ofc$1,728A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)2025
2025-04-23Janssen Research & Development, LLCCrdlgy Partners-Wellington Ofc$2,400A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)2025
2025-04-23Janssen Research & Development, LLCCrdlgy Partners-Wellington Ofc$16,999A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and 2025
2025-03-21Janssen Research & Development, LLCCrdlgy Partners-Wellington Ofc$22,690A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and 2025
2025-03-17Novartis Pharmaceuticals CorporationCARDIOLOGY PARTNERS CLINICAL RESEARCH INSTITUTE$147,341A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and 2025
2025-03-17Janssen Research & Development, LLCCrdlgy Partners-Wellington Ofc$1,200A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)2025
2025-03-14Janssen Research & Development, LLCCrdlgy Partners-Wellington Ofc$7,885A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and 2025
2025-02-25Eli Lilly and CompanyCARDIOLOGY PARTNERS CLINICAL$1,007THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SU2025
2025-02-24Janssen Research & Development, LLCCrdlgy Partners-Wellington Ofc$1,200A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)2025
2025-02-19Janssen Research & Development, LLCCrdlgy Partners-Wellington Ofc$17,755A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and 2025
2025-02-11Novartis Pharmaceuticals CorporationCARDIOLOGY PARTNERS, LLC$12,117A multi-center, randomized, double-blind placebo-controlled and open-label active-controlled, parallel-group, 24-week pr2025
2025-02-11Novartis Pharmaceuticals CorporationCARDIOLOGY PARTNERS, LLC$27,324A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo2025
2025-02-10Novartis Pharmaceuticals CorporationCARDIOLOGY PARTNERS CLINICAL RESEARCH INSTITUTE$51,362A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo2025
2025-01-30Novartis Pharmaceuticals CorporationCARDIOLOGY PARTNERS, LLC$27,350Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Car2025
2025-01-28Novartis Pharmaceuticals CorporationCARDIOLOGY PARTNERS, LLC$17,670A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With T2025
2025-01-27Eli Lilly and CompanyCARDIOLOGY PARTNERS CLINICAL$10,116A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION 2025
2025-01-22Janssen Research & Development, LLCCrdlgy Partners-Wellington Ofc$1,681A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)2025
2025-01-22Janssen Research & Development, LLCCrdlgy Partners-Wellington Ofc$23,187A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and 2025
2025-01-21Eli Lilly and CompanyCARDIOLOGY PARTNERS CLINICAL$113,480THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SU2025
2025-01-15Novartis Pharmaceuticals CorporationCARDIOLOGY PARTNERS, LLC$14,725A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With T2025
2025-01-13Novartis Pharmaceuticals CorporationCARDIOLOGY PARTNERS CLINICAL RESEARCH INSTITUTE$157,190Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Car2025
2025-01-07Eli Lilly and CompanyCARDIOLOGY PARTNERS CLINICAL$169,823A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION 2025
2024-12-23Bayer Healthcare Pharmaceuticals Inc.CARDIOLOGY PARTNERS CLINICAL RESEARCH INSTITUTE$331BAY 948862, A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy a2024
2024-12-18Janssen Research & Development, LLCCrdlgy Partners-Wellington Ofc$8,01270033093AFL30022024
2024-12-16Janssen Research & Development, LLCCrdlgy Partners-Wellington Ofc$46,08770033093AFL30022024
2024-12-16Janssen Research & Development, LLCCrdlgy Partners-Wellington Ofc$1,64470033093ACS30032024
2024-11-20Janssen Research & Development, LLCCrdlgy Partners-Wellington Ofc$30,84270033093AFL30022024
2024-11-19Bayer Healthcare Pharmaceuticals Inc.CARDIOLOGY PARTNERS CLINICAL RESEARCH INSTITUTE$2,763BAY 948862, A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy a2024
2024-11-18Janssen Research & Development, LLCCrdlgy Partners-Wellington Ofc$1,88470033093ACS30032024
2024-11-06Janssen Research & Development, LLCCrdlgy Partners-Wellington Ofc$6,89770033093AFL30022024
2024-10-23Janssen Research & Development, LLCCrdlgy Partners-Wellington Ofc$16,70370033093AFL30022024
2024-10-21Janssen Research & Development, LLCCrdlgy Partners-Wellington Ofc$2,40070033093ACS30032024
2024-10-08Bayer Healthcare Pharmaceuticals Inc.CARDIOLOGY PARTNERS CLINICAL RESEARCH INSTITUTE$4,524BAY 948862, A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy a2024
2024-10-02Janssen Research & Development, LLCCrdlgy Partners-Wellington Ofc$1,10470033093ACS30032024
2024-09-25Janssen Research & Development, LLCCrdlgy Partners$2,98770033093ACS30032024
2024-09-25Janssen Research & Development, LLCCrdlgy Partners$4,34570033093AFL30022024
2024-09-20Janssen Research & Development, LLCCrdlgy Partners$1,20070033093ACS30032024
2024-09-18Janssen Research & Development, LLCCrdlgy Partners$26,67070033093AFL30022024
2024-08-27Eli Lilly and CompanyCARDIOLOGY PARTNERS CLINICAL$3,427A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION 2024
2024-08-26Bayer Healthcare Pharmaceuticals Inc.CARDIOLOGY PARTNERS CLINICAL RESEARCH INSTITUTE$3,075BAY 948862, A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy a2024
2024-08-21Janssen Research & Development, LLCCrdlgy Partners$2,08970033093ACS30032024
2024-08-20Eli Lilly and CompanyCARDIOLOGY PARTNERS CLINICAL$49,888A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION 2024
2024-08-19Janssen Research & Development, LLCCrdlgy Partners$20,79970033093AFL30022024
2024-07-26Janssen Research & Development, LLCCrdlgy Partners$16,75070033093AFL30022024
2024-07-24Janssen Research & Development, LLCCrdlgy Partners$1,20070033093ACS30032024
2024-06-27Bayer Healthcare Pharmaceuticals Inc.CARDIOLOGY PARTNERS CLINICAL RESEARCH INSTITUTE$993BAY 948862, A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy a2024
2024-06-25Janssen Research & Development, LLCCrdlgy Partners$5,03470033093AFL30022024
2024-06-19Janssen Research & Development, LLCCrdlgy Partners$7570033093ACS30032024
2024-06-17Janssen Research & Development, LLCCrdlgy Partners$2,32970033093ACS30032024
2024-06-14Janssen Research & Development, LLCCrdlgy Partners$32,92270033093AFL30022024
2024-05-28Bayer Healthcare Pharmaceuticals Inc.CARDIOLOGY PARTNERS CLINICAL RESEARCH INSTITUTE$4,423BAY 948862, A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy a2024
2024-05-22Janssen Research & Development, LLCCrdlgy Partners$2,39670033093AFL30022024
2024-05-22Janssen Research & Development, LLCCrdlgy Partners$1,26170033093ACS30032024
2024-05-02Novartis Pharmaceuticals CorporationCARDIOLOGY PARTNERS CLINICAL RESEARCH INSTITUTE$33,791A multi-center, randomized, double-blind placebo-controlled and open-label active-controlled, parallel-group, 24-week pr2024
2024-04-26Janssen Research & Development, LLCCrdlgy Partners$3,95770033093AFL30022024
2024-04-26Janssen Research & Development, LLCCrdlgy Partners$3,89970033093ACS30032024
2024-04-23Bayer Healthcare Pharmaceuticals Inc.CARDIOLOGY PARTNERS CLINICAL RESEARCH INSTITUTE$761BAY 948862, A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy a2024
2024-04-11Bayer Healthcare Pharmaceuticals Inc.CARDIOLOGY PARTNERS CLINICAL RESEARCH INSTITUTE$2,968BAY 948862, A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy a2024
2024-03-25Janssen Research & Development, LLCCrdlgy Partners$18,74170033093AFL30022024

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Okeechobee CountyOkeechobee city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Okeechobee, FL, county Okeechobee County, FL, state Florida; placed by its city name.

MeasurePlace (city or town)
Okeechobee, FL
County
Okeechobee County, FL
State
Florida
Population B010035,47940,81622,416,077
Population, 2020 census P15,25439,64421,538,187
Median age B0100238.440.842.6
Under 18 B0100124.1%21.4%19.5%
65 and over B0100119.2%20.0%21.3%
Households B110012,05315,1138,752,810
Foreign born B0500210.2%13.4%21.9%
Median household income B19013$57,044$57,984$74,568
Median family income B19113$65,259$68,838$89,891
Per capita income B19301$27,942$28,796$42,609
Poverty rate B1700115.8%18.0%12.6%
Unemployment rate B230253.1%4.4%4.8%
Civilian labor force B230252,57416,69811,016,578
Mean commute (minutes) B0801325.628.428.0
Bachelor's degree or higher B1500321.1%15.8%34.1%
Housing units B250012,27318,57210,256,470
Owner-occupied B2500355.1%73.9%67.6%
Renters B2500344.9%26.1%32.4%
Median home value B25077$197,700$193,000$359,000
Median gross rent B25064$1,061$1,082$1,669
White, not Hispanic B0300251.4%61.8%50.4%
Black B030028.6%7.5%14.6%
Hispanic or Latino B0300234.0%26.1%27.4%
Asian B030020.9%0.7%2.9%
American Indian and Alaska Native B030020.1%0.3%0.1%

Economy now FRED unemployment 4.4% in Sep 2026 (4.2% a year earlier); per capita personal income $78,345 in 2025, up 38% in five years (+11.3% after inflation); Unemployment rate: 4.9% in Sep 2016 to 4.4% in Sep 2026; low 2.8%, high 14.1% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Okeechobee, FL.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.